IRBP (1-20), human (TFA)

OC(C(F)(F)F)=O.O=C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC(O)=O)C(O)=O)=O)CC(C)C)=O)CC(C)C)=O)C(C)C)=O)CCCCN)=O)C)=O)CCSC)=O)CC(O)=O)=O)CC(C)C)=O)C(C)C)=O)CC(C)C)=O)CO)=O)CCC1)=O)CCC(N)=O)=O)CC2=CC=CC=C2)=O)CC(C)C)=O)CC3=CN=CN3)=O)[C@@H](C)O)[C@H]4N(C(CN)=O)CCC4

[1]Avichezer D, et al. Residues 1-20 of IRBP and whole IRBP elicit different uveitogenic and immunological responses in interferon gamma deficient mice. Exp Eye Res. 2000;71 (2) :111‐118.|[2]Avichezer D, Silver PB, Chan CC, Wiggert B, Caspi RR. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Invest Ophthalmol Vis Sci. 2000;41 (1) :127‐131.